A single dose of vitamin D enhances immunity to mycobacteria
Martineau AR, Wilkinson RJ, Wilkinson KA, Newton SM, Kampmann B, Hall BM, Packe GE, Davidson RN, Eldridge SM, Maunsell ZJ, Rainbow SJ, Berry JL, Griffiths CJ
American journal of respiratory and critical care medicine · 272 citas
Etiquetas de revisión
Solo mecanismosDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Solo mecanismos
Quién lo pagó
- Financiación
- Financiación independiente
- Organización sin fines de lucro
- Wellcome Trust
- Gobierno
- Medical Research Council
- Subvenciones
- Wellcome Trust (077273); Wellcome Trust (072070); Wellcome Trust (066321); Wellcome Trust (064261)
Según 2 financiadores declarados.
Publicación
- Publicado
- 2007-04-26 · Am J Respir Crit Care Med · vol. 176 · número 2 · págs. 208–213
- Editorial
- American Thoracic Society
- Citado
- 408 citas · más que el 100% de estudios similares · 21.2× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 31 trabajos
- Acceso
- De pago
- Áreas de investigación
- Tuberculosis Research and Epidemiology · Vitamin D Research Studies · Immune responses and vaccinations
- Palabras clave
- vitamin D supplementation, antimycobacterial immunity, tuberculosis contacts, latent tuberculosis infection, IFN-gamma response, ESAT-6, CFP-10, vitamin D status
- MeSH
- humans, tuberculosis, vitamins, vitamin d, drug administration schedule, follow-up studies, double-blind method, dietary supplements, adult, aged, aged, 80 and over, middle aged, female, male, immunity, innate
13 autores
- Adrian R. Martineau🇬🇧Queen Mary University of London; London North West Healthcare NHS Trust; Northwick Park Hospital; Imperial College London; Wellcome Trust
- Robert John Wilkinson🇿🇦🇬🇧University of Cape Town; Institute of Infectious Disease and Molecular Medicine; Imperial College London; Wellcome Trust
- Katalin Andrea Wilkinson🇿🇦🇬🇧University of Cape Town; Institute of Infectious Disease and Molecular Medicine; Imperial College London; Wellcome Trust
- Sandra M. Newton🇬🇧Imperial College London; Wellcome Trust
- Beate Kampmann🇿🇦🇬🇧University of Cape Town; Institute of Infectious Disease and Molecular Medicine; Imperial College London; Wellcome Trust
- Bridget M. Hall
- Geoffrey E. Packe
- Robert N. Davidson🇬🇧Queen Mary University of London
- Sandra M Eldridge🇬🇧London North West Healthcare NHS Trust; Northwick Park Hospital
- Zoë Maunsell🇬🇧London North West Healthcare NHS Trust; Northwick Park Hospital
- Sandra J. Rainbow🇬🇧London North West Healthcare NHS Trust; Northwick Park Hospital
- Jacqueline Berry🇬🇧Manchester Royal Infirmary
- Chris Griffiths🇬🇧Queen Mary University of London
Resumen
El texto original del estudio, en el idioma en que se publicó.
Rationale
Vitamin D was used to treat tuberculosis (TB) in the preantibiotic era. Prospective studies to evaluate the effect of vitamin D supplementation on antimycobacterial immunity have not previously been performed.
Objectives
To determine the effect of vitamin D supplementation on antimycobacterial immunity and vitamin D status.
Methods
A double-blind randomized controlled trial was conducted in 192 healthy adult TB contacts in London, United Kingdom. Participants were randomized to receive a single oral dose of 2.5 mg vitamin D or placebo and followed up at 6 weeks.
Measurements and main results
The primary outcome measure was assessed with a functional whole blood assay (BCG-lux assay), which measures the ability of whole blood to restrict luminescence, and thus growth, of recombinant reporter mycobacteria in vitro; the readout is expressed as a luminescence ratio (luminescence postinfection/baseline luminescence). IFN-gamma responses to the Mycobacterium tuberculosis antigens early secretory antigenic target-6 and culture filtrate protein 10 were determined with a second whole blood assay. Vitamin D supplementation significantly enhanced the ability of participants' whole blood to restrict BCG-lux luminescence in vitro compared with placebo (mean luminescence ratio at follow-up, 0.57, vs. 0.71, respectively; 95% confidence interval for difference, 0.01-0.25; p=0.03) but did not affect antigen-stimulated IFN-gamma secretion.
Conclusions
A single oral dose of 2.5 mg vitamin D significantly enhanced the ability of participants' whole blood to restrict BCG-lux luminescence in vitro without affecting antigen-stimulated IFN-gamma responses. Clinical trials should be performed to determine whether vitamin D supplementation prevents reactivation of latent TB infection. Clinical trial registered with www.clinicaltrials.gov (NCT 00157066).
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.